Nearly two years in with Zurzuvae, Biogen tackles an ‘all of the above market’ to find patients and battle stigma in ...

R&D spending across the global pharmaceutical sector climbed 1.5% in 2024, according to unreleased data from Evaluate Pharma.

As the World Health Organization initiates a new agreement for coordinating global responses to future pandemics, the future ...

GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific ...

Acute systemic infection caused the patient to develop fatal capillary leak syndrome, highlighting the unpredictability of ...

According to President Trump, CMS Administrator Mehmet Oz is a “tough hombre” who can bring down drug costs “like a rock.” ...

Prothena has already discontinued the development of birtamimab, and anticipates further spending cuts, including workforce ...

The report takes from HHS Secretary Robert F. Kennedy Jr’s playbook, calling out rising autism rates, the vaccine schedule ...

In an opinion issued late Thursday night, U.S. District Judge Susan Illston wrote that the president and department agency ...

Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...

Analysts were effusive about Merus’ new HNSCC data, writing that petosemtamab could “become the standard of care” in the ...

The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...